Palvella Therapeutics granted sixth U.S. patent covering rapamycin

Palvella Therapeutics (PVLA) announced that the United States Patent and Trademark Office, USPTO, issued patent No. 12,329,748 for claims related to the Company’s lead product candidate QTORIN 3.9% rapamycin anhydrous gel. The patent provides broad protection for the proprietary anhydrous topical composition and methods of use for QTORIN rapamycin. “Our sixth issued U.S. patent marks another meaningful milestone in solidifying the exclusivity position of QTORIN(TM) rapamycin,” said Wes Kaupinen, Founder and Chief Executive Officer of Palvella. “We’re executing a multi-layered strategy to protect and maximize the long-term value of QTORIN rapamycin-anchored by strong intellectual property, proprietary formulation and manufacturing trade secrets, and regulatory exclusivities.”